ATI 2173
Alternative Names: ATI-2173Latest Information Update: 28 Mar 2023
At a glance
- Originator Emory University
- Developer Antios Therapeutics
- Class Antivirals; Arabinonucleosides; Phosphoramidic acid; Pyrimidine nucleosides; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Hepatitis-B in Canada (PO, Capsule)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Hepatitis-B in Moldova (PO, Capsule)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Hepatitis-B in Ukraine (PO, Capsule)